前列腺癌（prostate cancer，PCa）是欧美国家男性最常见恶性肿瘤。雄激素剥除治疗（ADT） 最初治疗晚期PCa 患者有效，最终会进展为去势抵抗型前列腺癌（CRPC）。CRPC 患者临床预后差，疗效不 佳。近年免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）应用于晚期 PCa 治疗取得成功，现就 ICIs 在晚期PCa 治疗中的进展进行综述，并探讨其发展方向与应用前景。

Prostate cancer（PCa）is most common among American and European males. Advanced PCa patients are witnessed to be effectively treated with androgen deprivation therapy（ADT）at the preliminary stage and it eventually develops to the castration⁃resistant prostate cancer（CRPC），which results in poor prognosis. In recent years，immune checkpoint inhibitors（ICIs）have been successfully applied in the treatment of advanced PCa. In this paper，we have reviewed the literature on ICIs′ role in the treatment of advanced PCa，and discussed its development directions and application prospects.